Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2022

Genmab — Februar 2022

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #9

    Thanks E L. 🙂

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #10

      Aktier/middag: Grøn dag - Novozymes i den røde ende efter tal
      https://www.proinvestor.com/investornyt/774155/aktier-middag-gron-dag-novozymes-i-den-rode-ende-efter-tal

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #11

        ØU Investor has a new Genmab analysis for the members

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #12

          Biogen Inc. (Nasdaq: BIIB) today announced that it exercised its option to participate in the development and commercialization of mosunetuzumab. Biogen will pay a $30 million one-time option fee to Genentech, a member of the Roche Group, as part of the companies’ long-standing collaboration on antibodies targeting CD20. https://investors.biogen.com/news-releases/news-release-details/biogen-exercises-option-participate-development-and

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #13

            I did not know that Genentech/Roche had a CD20 collaboration with Biogen

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #14

              neither did I...

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #15

                Do Biogen then sell Rituxan, Gazyva and Ocrevus?

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #16

                  i think they have profit share agreements yes, it is a bit messy, i think they had a dispute about it a while back

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #17

                    update of the EPCORE CLL-1 trial, adding 1 arm to focus on Richter's Syndrome https://clinicaltrials.gov/ct2/history/NCT04623541?A=3&B=4&C=merged#StudyPageTop https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/richters-syndrome

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #18

                      New spanish Maintenance trial with Bortezomib Plus Daratumumab (V-Dara) https://clinicaltrials.gov/ct2/show/NCT05218603

                      1 Reply Last reply
                      0
                      • R Offline
                        R Offline
                        RossGeller
                        wrote on sidst redigeret af
                        #19

                        EL is the ØU analysis available now?

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #20

                          if you go to their site ugebrev it should be there for members (not me 😉 )

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #21

                            God morgen. 🙂

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              ProinvestorNEWS
                              wrote on sidst redigeret af
                              #22

                              Asien: Markant positiv positiv påvirkning fra Wall Street - NY
                              https://www.proinvestor.com/investornyt/774792/asien-markant-positiv-positiv-pavirkning-fra-wall-street-ny

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #23

                                Onsdagens aviser med Novozymes, Danske Bank og FLSmidth - NY
                                https://www.proinvestor.com/investornyt/774796/onsdagens-aviser-med-novozymes-danske-bank-og-flsmidth-ny

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  ProinvestorNEWS
                                  wrote on sidst redigeret af
                                  #24

                                  Obligationer/tendens: Fortsat høj rente i sigte med fokus på inflation
                                  https://www.proinvestor.com/investornyt/774799/obligationer-tendens-fortsat-hoj-rente-i-sigte-med-fokus-pa-inflation

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #25

                                    Kesimpta Full year USD 372 million (Q4 USD 147 million) sales were driven by launch uptake, strong access and increased
                                    demand based on a superior benefit-risk profile; now approved in 64 countries

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #26

                                      novartis press release

                                      https://www.novartis.com/news/media-releases/novartis-delivers-mid-single-digit-sales-growth-margin-expansion-and-advancement-robust-pipeline-2021 and presentation https://www.novartis.com/sites/novartis_com/files/q4-2021-investor-presentation.pdf

                                      1 Reply Last reply
                                      0
                                      • D Offline
                                        D Offline
                                        deleted-user
                                        wrote on sidst redigeret af
                                        #27

                                        Pretty strong acceleration

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #28

                                          yes, and 64 countries already is impressive. and I assume there will be no sales 'free of charge'
                                          anymore in 2022

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper